News
Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, ...
The Window of Opportunity: Why Early Biologic Use Matters for Patients With Hidradenitis Suppurativa
Panelists discuss the critical importance of early biologic therapy initiation in hidradenitis suppurativa to prevent irreversible tissue damage, reduce disease burden, and overcome socioeconomic and ...
Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Study Overview: Incyte Corporation is conducting a Phase ...
TipRanks on MSN8h
Incyte’s Phase 3 Study on Ruxolitinib Cream: A Potential Breakthrough for Hidradenitis Suppurativa
Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation is conducting a Phase 3 clinical study ...
Avalo Therapeutics (NASDAQ:AVTX) stock rises as Cantor Fitzgerald launches coverage with an Overweight rating, highlighting its lead asset, AVTX-009. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback